ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance

by Oryzon Genomics

2 months ago
LSD1 inhibitor, Vafidemstat, borderline personality disorder (BPD)

Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder

ORYZON reports financial results and corporate update for half-year ending June 30, 2025

by Oryzon Genomics

10 months ago
Vafidemstat, Iadademstat, Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1.8 M from R&D cash-back incentives), ORYZON

Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant...

ORYZON continues to strengthen its patent portfolio for vafidemstat.

by Oryzon Genomics

1 year ago
vafidemstat

The patent, titled “Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat”, covers the use Oryzon’s LSD1 inhibitor, vafidemstat, cu...

ORYZON reports financial results and corporate update for Q4 2024

by Oryzon Genomics

1 year ago
Vafidemstat, Iadademstat, Oryzon

Oryzon Genomics, S.A, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fou...

ORYZON reports financial results and corporate update for quarter ended September 30, 2024

by Oryzon Genomics

2 years ago
Vafidemstat, Iadademstat, Oryzon

Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the nine months...

ORYZON announces formal grant of key European patent for vafidemstat

by Oryzon Genomics

2 years ago
borderline personality disorder (BPD), schizophrenia, Vafidemstat, EP3661510B1

Oryzon announced today that the European Patent Office (EPO) has now formally granted Oryzon’s European patent EP3661510B1, titled “Methods of treating behavior alterations” related to vafidemst...

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

by Oryzon Genomics

2 years ago
vafidemstat, Borderline Personality Disorder (BPD)

Oryzon Genomics announced today the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in Borderline Personality Disorder (BPD) with the US Food and Drug Adm...

ORYZON presents the final data from PORTICO, a global Phase IIb vafidemstat trial in Borderline Personality Disorder (BPD), at the European College of Neuropsycopharmacology (ECNP) congress

by Oryzon Genomics

Oryzon announced that it will present today the final data from its Phase IIb PORTICO trial of vafidemstat in patients with Borderline Personality Disorder (BPD) as an oral presentation at the New Med...

ORYZON receives 'Intention to grant' communication for patent relating to the use of vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

2 years ago
vafidemstat, Oryzon, European patent

Oryzon Genomics announced today that the European Patent Office (EPO) has issued an “intention to grant” communication for Oryzon’s European patent application EP20712565.9 entitled “Methods o...

ORYZON secures another important patent for its lead CNS asset, vafidemstat

by Oryzon Genomics

2 years ago
EP18748921.6, vafidemstat

It Has been received “Intention to Grant” from the European Patent Office for the treatment of aggression and social withdrawal

ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million

by Oryzon Genomics

3 years ago
Nice & Green, SA, vafidemstat, Oryzon Genomics

Funding provided by Nice & Green SA, a Swiss private investor, of €8 million in two tranches of €4 million each, plus optional additional tranches of up to €5 million each to be executed in the ...

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

3 years ago
borderline personality disorder (BPD), Phase IIb PORTICO, vafidemstat

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company presented an ...